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Gene therapy has been billed as a method of curing most humandiseases. Despite a large amount of initial enthusiasm and a vastamount of resources spent in this area, however, except in isolatedcases gene-directed treatment has yielded only modest or littlesuccess. Indeed, there have been several instances in which genetherapy has resulted in adverse events and even death. Why the
limited success despite initial optimism? As with most clinical issues or problems,
the answer is multifactorial. With gene therapy, it is hypothesized that by the
introduction of a piece of genetic material (DNA) into the host genome, the host will
be able to produce enough of a protein through translation from the resultant
messenger RNA to provide beneficial results. These results can be increased blood
vessel growth through angiogenesis, providing a deficient vital protein involved in
immune defense, or increasing the body’s ability to tolerate oxidative stress in the
heart after ischemia.
First, the genetic material (DNA) needs to be incorporated into the host genome.
Some investigators have attempted to inject naked DNA encoding a certain protein
into the tissue at various isolated areas and have reported fairly dramatic effects. I
am personally somewhat skeptical that this approach will ever have much of a role
in the treatment of patients. The efficiency of transfection, or the incorporation of
the DNA into the genome, is extremely low with this method, and the local delivery
of the DNA to such a small locus is not likely to have a widespread effect. However,
other methods of gene delivery have been more successful. Second, a promoter,
either native or exogenous, needs to be present to produce, or transcribe, a signif-
icant amount of messenger RNA. Messenger RNA, as opposed to DNA, is not stable
and rapidly breaks down chemically through the activation of one of several
degradation enzymes. This makes teleologic sense, because a genetic message in the
form of messenger RNA should not hang around forever. The body needs to
constantly reassess the local environment and make modifications in the cellular
milieu. Third, from the messenger RNA a protein is translated. This process is also
under the tight control of other structural proteins and enzymes. The protein is also
subject to degradation through the activation of proteosomes and other enzymes.
Fourth, the protein product then acts on the cells, usually through transmembrane
receptors, and produces some signal or change the structure of the tissue. Finally, it
is assumed that the protein encoded by the DNA will indeed cure the patient or at
least have a positive effect. Enough of the protein needs to be around for long
enough to provide a significant benefit. If any of these processes is interrupted, or
if the protein actually has no effect in vivo, gene therapy will fail.
The optimal method for introduction of the DNA into the host genome has been
debated and depends on the clinical situation. Injection of naked DNA strands with
a syringe, as mentioned previously, is certainly the simplest method, but the efficacy
of transfection is low and the DNA tends to be present for only a few days. Little
protein tends to be produced. Viral vectors make the process much more efficient.
The adenoviral vector is often used to move the DNA into the cell and cause its
incorporation into the host genome. Expression may be extended to several weeks
with adenoviral vectors. However, native circulating antibodies to the virus that are
often present in the blood may neutralize the vector and markedly reduce the
expression of the gene. Other viral vectors have other advantages and disadvantages
relative to adenovirus. Some viral vectors, such as adenoassociated virus and
lentivirus, may produce more prolonged expression. In many cases that may not be
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optimal, however, because large amounts of a protein may
have toxic manifestations. There has been work done on
viral vectors that may be regulated, but the applications to
the clinical situation are still preliminary. Finally, the tox-
icities of the DNA and viral vectors are not completely
understood. An unlikely but theoretically possible scenario
is that a noninfective viral vector will go haywire and
transmit a lethal gene to the general population.
Cell-based gene therapy is a promising new strategy that
uses autologous cells transfected with a transgene of interest
to express that transgene in vivo. Complex multigene vec-
tors can be generated that allow stable, regulatable gene
expression. Other nonviral methods for the introduction of
DNA into the host genome, such as phospholipid liposomes,
do show some promise but as yet have failed to provide a
marked advantage relative to viral vectors.
Protein therapy, on the other hand, skips most of the
steps involved in transfection, transcription, and translation
and only assumes that the protein is effective treating the
ailment and can be provided in high enough concentration
and duration to be effective. The toxicity profiles of proteins
are, in general, better understood than those of genetic
material. However, long-term delivery is difficult with pro-
teins and depends on the biologic half-life of the molecule
in vivo. Therefore repeated delivery of sustained delivery
through the use of implantable devices or repeated injec-
tions may be required for optimal therapy.1,2
Despite these limitations and potential problems, there
have been a relatively large number of recent publications
documenting the potential of gene therapy in cardiac sur-
gery. I will summarize just a few of these studies. Rosengart
and colleagues3 have demonstrated improved (albeit
slightly) anginal symptoms after the injection of vascular
endothelial growth factor DNA with the adenoviral vector
through increased collateral development. Thus blood ves-
sel formation may be increased and coronary insufficiency
may be treated with gene therapy in patients who would not
be considered as surgical candidates. With regard to the
peripheral circulation, Baumgartner and associates4 from St
Elizabeth’s Hospital in Boston reported that the constitutive
expression of vascular endothelial growth factor after intra-
muscular gene transfer promotes collateral vessel develop-
ment in patients with limb ischemia. Although in theory this
would improve peripheral blood flow, the outcome vari-
ables were vague, and a placebo was not used.
One concern is always that transfection efficacy will not
be sufficient to allow the protein to be produced. However,
Logeart and colleagues5 were able to show highly efficient
adenovirally mediated gene transfer to cardiac myocytes
after single-pass coronary delivery in rats, suggesting that
gene transfer methods may be applicable to the intraopera-
tive situation. In addition, Davidson and coworkers6 from
Duke found that they could deliver transgenes to the 2-
adrenergic receptor in the pig through the aortic cardiople-
gia delivery cannula after the induction of arrest. Although
protein receptor levels were increased in the myocardium,
no assessment of improved ventricular function was made.
In a similar study Bridges and associates7 reported that
cardiac-specific transgene expression could be obtained
with cardiac isolation within 15 to 30 minutes. Wang and
colleagues8 compared direct infection and perfusion as
methods of delivering a transgene with an adenoviral vector.
Although direct injection resulted in overall more efficient
delivery, a more uniform distribution was evident with
intra-aortic perfusion.
Zhu and coworkers9 demonstrated the blocking of free
radical production by transfer of genes encoding catalase.
This group from the University of Pennsylvania (Gardner
and Sweeney) has published a large number of elegant
studies showing that transfection of various genes may
improve tolerance to ischemic injury in animals. Gene ther-
apy may also show some promise in modifying vascular
grafts and improving patency after coronary and peripheral
bypass surgery. For example, Cable and coworkers10 at the
Mayo Clinic showed that the transfer of nitric acid synthase
gene to vascular grafts could reduce intima hyperplasia in
human vein and arterial tissue in culture.
Although these examples show how gene therapy could
potentially be applied to cardiovascular disease, overall
clinical studies demonstrating improved myocardial func-
tion after a genetic intervention are lacking. The study by
Abunasra and colleagues11 published in this issue of the
Journal examined donor rat hearts perfused with a hypo-
thermic solution containing adenoviral vector carrying the
genes for endothelial nitric oxide synthase, manganese su-
peroxide dismutase, or both. Four days later, transplanted
hearts were collected, isolated in the Langendorff prepara-
tion, and subjected to 6 hours of ischemia followed by 1
hour of reperfusion. Both endothelial nitric oxide synthase
and manganese superoxide dismutase expressions were in-
creased by gene transfer. Function after ischemia-reperfu-
sion was increased with transfection of either gene, but not
the combination. This study was well performed, but similar
findings have been demonstrated with nitric oxide donors
such as L-arginine and nitroglycerin or various forms of
superoxide dismutase. The new aspect to this study is that
the substances were delivered by gene therapy. It has been
estimated that there are about 10,000 articles dealing with
myocardial protection with additives to cardioplegic solu-
tions, blood versus crystalloid cardioplegia, warm versus
cold versus tepid cardioplegia, complement antibodies, neu-
trophil filters, and so on. Does anyone currently add any-
thing but blood to a cardioplegic solution except for re-
search purposes? There have been almost no studies to
demonstrate a clinical benefit of adding a substance to the
cardioplegic solution, despite a multitude of articles report-
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ing a significant benefit in animals with lidocaine, propran-
olol, adenosine, and many other compounds. Since addi-
tives to cardioplegic solutions add little or no clinical benefit
to the health of patients, would we expect the same sub-
stances delivered by gene therapy to do anything different?
The article in this issue deals with a rat model of cardiac
transplantation. Will more hearts become available if we
can increase the donor pool by increasing the amount of
time allowed to transport a donor heart? With so few donor
hearts available anyway, I suspect that the answer is no.
This is not to say that research directed toward improving
tolerance of myocardium to an ischemic insult is not valu-
able work. However, it remains to be seen what gene
therapy will actually do to expand therapeutic options and
improve the health of patients.
There are several considerations that need to be ad-
dressed before gene therapy or any new therapy is subjected
to clinical trials or use of the new therapy becomes wide-
spread.12,13 Investigators need to ensure adequate protection
of human subjects in clinical research in general, and in
gene therapy trials specifically they need to ensure ethical
conduct of research. First, researchers need to be certain that
subjects fully understand all the potential risks of a clinical
trial. Patients who do not understand the potential risks of a
trial cannot be said to have chosen freely to face those risks.
Second, the Food and Drug Administration has identified
cases in which researchers failed to disqualify subjects who
did not meet the criteria for a gene therapy study, failed to
report adverse events as required, failed to ensure that a
protocol was followed, and failed to ensure that study staff
had adequate training. This procedure needs to be closely
monitored and maintained. Third, institutional review
boards, the key element of the system to protect research
subjects, have excessive workloads and inadequate re-
sources. Thus adequate evaluation of protocols may not
have occurred before the initiation of the trial. Finally,
conflicts of interest and ethical dilemmas arise because
academic researchers serve as both investigators and spon-
sors or patent holders of products. The researcher’s self-
interest may influence his or her scientific judgment.
In addition to the protection of study subjects, studies of
gene therapy should consider the following issues12,13:
● The placebo effect is extremely powerful in patients
with end-stage cardiac disease.
● Randomized clinical trials are powerful tools for elim-
inating confounding variables but cannot reduce inves-
tigator bias or the placebo effect.
● Patient and investigator blinding would eliminate the
placebo effect and investigator bias, effectively reduce
crossover (which dilutes treatment effect), and mini-
mize differences in other aspects of medical care.
● Blinding of studies involving patients with end-stage
cardiac disease may be perceived as unethical. How-
ever, this caveat may be overcome by thoughtful study
design. It is probably more ethical to enroll a few
patients in a well-designed and adequately powered
placebo-controlled study than to treat hundreds of pa-
tients with a treatment that is later shown to be inef-
fective.
● No-option patients (those with end-stage coronary ar-
tery disease or heart failure) may also exhibit a “phys-
iologic placebo effect” whereby ineffective treatment
induces symptomatic relief paralleled by improved ex-
ercise tolerance, improved cardiac conditioning, and
potential improved collateralization or myocardial
contractile function.
There have been several recent cases in which investi-
gators did not follow the guidelines, and they have suffered
the consequences. Before further clinical work is initiated in
the area of gene therapy, we need to standardize the eval-
uation of efficacy and ensure adequate protection of sub-
jects. Gene therapy offers a tremendous opportunity to
improve the care of critically ill patients with heart disease.
However, its exact role remains to be seen. The overzealous
enthusiasm of the investigators should not get in the way of
the optimal care of the patients. Strict guidelines need to be
followed with gene therapy trials as with most other clinical
trials. The efficacy of a treatment needs to be verified before
gene therapy is applied. If a protein is not effective for the
treatment of a cardiac illness, the administration of an
adenoviral vector is not likely to provide much benefit to the
patient.
References
1. Sellke FW, Simons M. Angiogenesis in cardiovascular disease: cur-
rent status and therapeutic potential. Drugs. 1999;58:391-6.
2. Ruel M, Laham RJ, Parker JA, Post MJ, Ware JA, Simons M, et al.
Long-term effects of surgical angiogenic therapy with fibroblast
growth factor 2 protein. J Thorac Cardiovasc Surg. 2002;124:28-
34.
3. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman
GW, et al. Angiogenesis gene therapy: phase 1 assessment of direct
intramyocardial administration of an adenovirus vector expressing
VEGF121 cDNA to individuals with clinically significant severe cor-
onary artery disease. Circulation. 1999;100:468-74.
4. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K,
et al. Constitutive expression of phVEGF165 after intramuscular gene
transfer promotes collateral vessel development in patients with crit-
ical limb ischemia. Circulation. 1998;97:1114-23.
5. Logeart D, Hatem SN, Rucker-Martin C, Chossat N, Nevo N,
Haddada H, et al. Highly efficient adenovirus-mediated gene transfer
to cardiac myocytes after single-pass coronary delivery. Hum Gene
Ther. 2002;11:1015-22.
6. Davidson MJ, Jones JM, Emani SM, Wilson KH, Jaggers J, Koch WJ,
et al. Cardiac gene delivery with cardiopulmonary bypass. Circula-
tion. 2001;104:131-3.
7. Bridges CR, Burkman JM, Malekan R, Konig SM, Chen H, Yarnall
CB, et al. Global cardiac-specific transgene expression using cardio-
pulmonary bypass with cardiac isolation. Ann Thorac Surg. 2002;73:
1939-46.
8. Wang J, Ma Y, Knechtle SJ. Adenovirus-mediated gene transfer into
Editorials Sellke
996 The Journal of Thoracic and Cardiovascular Surgery ● May 2003
ED
ITO
RIA
L
rat cardiac allografts: comparison of direct injection and perfusion.
Transplantation. 1996;61:1726-9.
9. Zhu HL, Stewart AS, Taylor MD, Vijayasarathy C, Gardner TJ, Sweeney
HL. Blocking free radical production via adenoviral gene transfer de-
creases cardiac ischemia-reperfusion injury. Mol Ther. 2000;2:470-5.
10. Cable DG, Caccitolo JA, Caplice N, O’Brien T, Simari RD, Daly RC,
et al. The role of gene therapy for intimal hyperplasia of bypass grafts.
Circulation. 1999;100(19 Suppl):II392-6.
11. Abunasra HJ, Smolenski RT, Yap J, Sheppard M, O’Brien T, Yacoub
MH. Multigene adenoviral therapy for the attenuation of ischemia-
reperfusion injury after preservation for cardiac transplantation. J Tho-
rac Cardiovasc Surg. 2003;125:998-1006
12. Laham RJ, Simons M, Sellke FW. Gene transfer for angiogenesis in
coronary artery disease. Annu Rev Med. 2001;52:485-502.
13. Shalala D. Protecting research subjects—what must be done. N Engl
J Med. 2000;343:808-10.
Sellke Editorials
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 5 997
ED
IT
O
RI
A
L
